Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy.
Tschirdewahn S, Wiesenfarth M, Bonekamp D, Püllen L, Reis H, Panic A, Kesch C, Darr C, Heß J, Giganti F, Moore CM, Guberina N, Forsting M, Wetter A, Hadaschik B, Radtke JP. Tschirdewahn S, et al. Among authors: wetter a. Eur Urol Focus. 2021 Nov;7(6):1300-1307. doi: 10.1016/j.euf.2020.06.020. Epub 2020 Jul 11. Eur Urol Focus. 2021. PMID: 32660838
Three-dimensional Magnetic Resonance Imaging-based Printed Models of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Patient-tailored Radical Prostatectomy-A Feasibility Study.
Darr C, Finis F, Wiesenfarth M, Giganti F, Tschirdewahn S, Krafft U, Kesch C, Bonekamp D, Forsting M, Wetter A, Reis H, Hadaschik BA, Haubold J, Radtke JP. Darr C, et al. Among authors: wetter a. Eur Urol Oncol. 2022 Jun;5(3):357-361. doi: 10.1016/j.euo.2020.08.004. Epub 2020 Aug 29. Eur Urol Oncol. 2022. PMID: 32873530
Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial.
Saner YM, Wiesenfarth M, Weru V, Ladyzhensky B, Tschirdewahn S, Püllen L, Bonekamp D, Reis H, Krafft U, Heß J, Kesch C, Darr C, Forsting M, Wetter A, Umutlu L, Haubold J, Hadaschik B, Radtke JP. Saner YM, et al. Among authors: wetter a. Eur Urol Oncol. 2023 Feb;6(1):49-55. doi: 10.1016/j.euo.2022.08.005. Epub 2022 Sep 26. Eur Urol Oncol. 2023. PMID: 36175281 Clinical Trial.
Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A. Guberina N, et al. Among authors: wetter a. Mol Imaging Biol. 2020 Jun;22(3):788-796. doi: 10.1007/s11307-019-01424-4. Mol Imaging Biol. 2020. PMID: 31482413
Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
Al-Bayati M, Grueneisen J, Lütje S, Sawicki LM, Suntharalingam S, Tschirdewahn S, Forsting M, Rübben H, Herrmann K, Umutlu L, Wetter A. Al-Bayati M, et al. Among authors: wetter a. Urol Int. 2018;100(2):164-171. doi: 10.1159/000484695. Epub 2018 Jan 25. Urol Int. 2018. PMID: 29393268
68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. Farolfi A, et al. Among authors: wetter a. J Urol. 2019 Dec;202(6):1174-1181. doi: 10.1097/JU.0000000000000417. Epub 2019 Jun 24. J Urol. 2019. PMID: 31233369
150 results